Skip to content
HowShorted

Keros Therapeutics, Inc. short interest in 2024

In 2024, Keros Therapeutics, Inc.'s disclosed short interest ran from 4.85% of shares outstanding on 12 Jan 2024 to 10.65% on 31 Dec 2024, a change of +5.80 percentage points. The year's high was 10.65% on 31 Dec 2024 and its low 4.85% on 12 Jan 2024, averaging 7.22% across 24 twice-monthly settlement dates. FINRA's days-to-cover figure peaked at 14.44 days on 30 Aug 2024. Full history: Keros Therapeutics, Inc..

Cite this page
Plain
Wikipedia
BibTeX

By year: 2020 · 2021 · 2022 · 2023 · 2024 · 2025 · 2026

Aggregate net short position time series for Keros Therapeutics, Inc. in 2024

2024 in figures

Start of year
4.85% (12 Jan 2024)
End of year
10.65% (31 Dec 2024)
Change
+5.80 pp
High
10.65% (31 Dec 2024)
Low
4.85% (12 Jan 2024)
Average
7.22%
Highest days to cover
14.44 (30 Aug 2024)
SEC filings marked
8

Every report in 2024

Keros Therapeutics, Inc. short interest in 2024
SettlementShort interestDays to coverFilings since previous
12 Jan 20244.85%1.97
31 Jan 20245.90%4.54
15 Feb 20245.95%4.17
29 Feb 20246.03%4.8710-K filed, results (8-K)
15 Mar 20246.42%3.95
28 Mar 20247.02%6.27
15 Apr 20247.53%9.80
30 Apr 20247.64%7.76
15 May 20246.73%8.1410-Q filed, results (8-K)
31 May 20246.51%9.48
14 Jun 20247.22%8.14
28 Jun 20247.07%4.61
15 Jul 20247.95%8.17
31 Jul 20248.44%8.77
15 Aug 20249.29%11.2710-Q filed, results (8-K)
30 Aug 20249.09%14.44
13 Sep 20249.32%8.24
30 Sep 20248.04%7.50
15 Oct 20247.25%9.21
31 Oct 20245.95%7.70
15 Nov 20245.49%4.8510-Q filed, results (8-K)
29 Nov 20245.42%5.81
13 Dec 20247.47%1.28
31 Dec 202410.65%3.19

See also: Keros Therapeutics, Inc.'s full history · most shorted US stocks of 2024 · today's US league.

About this data

US short interest data: FINRA (finra.org), shown as reported shares short divided by SEC-reported shares outstanding for each settlement date. FINRA® is a registered trademark of the Financial Industry Regulatory Authority, Inc. This site is not affiliated with or endorsed by FINRA or the SEC; displayed for personal reference, bulk redistribution is not permitted (see terms). Nothing here is investment advice. Method: methodology.